[HTML][HTML] SARS-CoV-2 variant biology: immune escape, transmission and fitness
AM Carabelli, TP Peacock, LG Thorne… - Nature Reviews …, 2023 - nature.com
In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …
[HTML][HTML] Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta …
Background The global surge in the omicron (B. 1.1. 529) variant has resulted in many
individuals with hybrid immunity (immunity developed through a combination of SARS-CoV …
individuals with hybrid immunity (immunity developed through a combination of SARS-CoV …
[HTML][HTML] Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients
Background COVID-19 is associated with increased risks of neurological and psychiatric
sequelae in the weeks and months thereafter. How long these risks remain, whether they …
sequelae in the weeks and months thereafter. How long these risks remain, whether they …
Cognition and memory after Covid-19 in a large community sample
A Hampshire, A Azor, C Atchison… - … England Journal of …, 2024 - Mass Medical Soc
Background Cognitive symptoms after coronavirus disease 2019 (Covid-19), the disease
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are well …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are well …
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling …
Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …
[HTML][HTML] Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Background Understanding the level and characteristics of protection from past SARS-CoV-
2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe …
2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe …
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Immunological memory is the basis of protective immunity provided by vaccines and
previous infections. Immunological memory can develop from multiple branches of the …
previous infections. Immunological memory can develop from multiple branches of the …
Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1. 529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California
Epidemiologic surveillance has revealed decoupling of Coronavirus Disease 2019 (COVID-
19) hospitalizations and deaths from case counts after emergence of the Omicron (B. 1.1 …
19) hospitalizations and deaths from case counts after emergence of the Omicron (B. 1.1 …
COVID-19, myocarditis and pericarditis
DL Fairweather, DJ Beetler, DN Di Florio… - Circulation …, 2023 - Am Heart Assoc
Viral infections are a leading cause of myocarditis and pericarditis worldwide, conditions that
frequently coexist. Myocarditis and pericarditis were some of the early comorbidities …
frequently coexist. Myocarditis and pericarditis were some of the early comorbidities …
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis …
Background Synthesising evidence on the long-term vaccine effectiveness of COVID-19
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …